logo-loader
viewBiocept Inc

Biocept promotes Cory Dunn to senior vice president of commercial operations

Dunn, who served as vice president of commercial operations since October 2018, succeeds Edwin Hendrick

Biocept Inc - Biocept promotes Cory Dunn to senior vice president of commercial operations
Her promotion comes as Biocept advances the usage of its flagship Target Selector liquid biopsy tests

Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests, has promoted Cory Dunn to senior vice president of commercial operations. 

Dunn succeeds Edwin Hendrick, who resigned to pursue other endeavors, the San Diego-based company said in a statement Friday. 

She has served as Biocept's vice president of commercial operations since October 2018. Prior to joining Biocept, she held multiple leadership positions at life sciences companies specializing in diagnostics, including GenomeDx Biosciences (now Decipher Biosciences), PLUS Diagnostics (now Inform Diagnostics) and Genoptix. 

READ: Biocept partners with California physician association to provide cancer testing

Dunn holds an MA in education from Stanford University, and MS in Biology and BS in Biochemistry and Cell Biology from the University of California, San Diego.

Her promotion comes as Biocept advances the usage of its flagship Target Selector technology platform, which collects and analyzes molecular markers linked to tumors in circulating tumor cells as well as plasma to identify cancer mutations. The assays detect lung, breast, gastric, colorectal and prostate cancers as well as melanoma. 

"Cory has done a fantastic job over the past several years in expanding our Target Selector strategy into urology and oncology, and we are delighted that she will head our commercial operations," said CEO Michael Nall.

"The entire team is united behind Cory's sales and marketing leadership and we look forward to providing updates on our commercial progress. I want to thank Edwin Hendrick for his leadership and dedication to Biocept and we wish him all the best in his future endeavors."

Dunn added: "I look forward to taking on this new challenge and am enthusiastic about working with the commercial team to expand Biocept's reach and the universe of patients who can benefit from our Target Selector testing." 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 0.279 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $30.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Biocept reveals second contract for assay services after...

Biocept Inc (NASDAQ: BIOC) CEO Mike Nall says the San Diego-based biotech firm delivered revenue of $1.8 million during 4Q 2019, an increase of 108% over the same period last year, before it unveiled a second contract for its assay services with California independent physician...

1 week, 4 days ago

2 min read